Delivery Order SPE2DB22D3501-SPE2DB24FWC32

Award Date 6/27/24
Potential Completion Date 6/28/24
Potential Value $1.7K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Gadavist, a medical imaging contrast agent. The $1,189.28 firm fixed-price contract has a completion date of September 23, 2022 and is not designated as a set-aside. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical through November 2026, as well as a $750,000 IDC with the Department...
The U.S. Defense Logistics Agency (DLA) awarded a delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, for the supply of the pharmaceutical product Gadavist (10 mL vial). The $5,505.64 firm-fixed-price contract has an ultimate completion date of August 24, 2022. Amerisourcebergen holds a larger $999,999,999.00 Indefinite Delivery Contract (IDC) with DLA Troop Support Medical as the primary vehicle for delivering a range of pharmaceutical and...
This is a $1,040.96 firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is to supply the drug Gadavist, a contrast agent used in medical imaging procedures. The delivery order is part of a larger Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA Troop Support Medical, valued at $999,999,999 and running through November...
This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the procurement of Gadavist, a pharmaceutical product, with a ceiling value of $1,062.40 and an ultimate completion date of January 21, 2025. The contract is a firm-fixed-price delivery order, which is not designated as a set-aside. AmerisourceBergen holds a significant Indefinite Delivery...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp's Corporate Office Division. The $1,711.35 Firm Fixed Price Delivery Order is for the supply of Gadavist, a 1 mmol/ml bulk vial medication, with a performance period through June 13, 2024. AmerisourceBergen, a major pharmaceutical distribution company, holds a single-award Indefinite Delivery Contract (IDC) valued up to $999,999,999.00 with DLA Troop Support Medical to provide a...
This federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, was issued by the Defense Logistics Agency (DLA) Troop Support Medical. The $1,846.18 firm fixed price delivery order is for the supply of 30 mL bulk vials of the medication Gadavist, a contrast agent used in medical imaging. The contract has a period of performance through March 18, 2025 and was not designated with a set-aside requirement. Amerisourcebergen holds a larger $999,999,999 Indefinite...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,942.00, is for the procurement of Gadavist, a 10 milliliters per vial medical product, with a performance period through January 8, 2024. This contract award is associated with Amerisourcebergen's Indefinite Delivery Contract (IDC) with the DLA Troop...
This federal contract award was issued by the Defense Logistics Agency (DLA) to the prime contractor Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation. The $1,164.96 firm fixed price delivery order is for the supply of the pharmaceutical product Gadavist 7.5 mmol/7.5 ml vial, with an ultimate completion date of April 10, 2024. Amerisourcebergen Drug Corp holds an Indefinite Delivery Contract (IDC) with DLA, valued at up to $999,999,999.00 through December 31, 2025....
This is a firm fixed price delivery order awarded by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, as the prime contractor. The contract is for the delivery of Gadavist, a pharmaceutical product, with a ceiling value of $2,330.40 and a performance period through April 8, 2024. Amerisourcebergen Drug Corp holds an indefinite delivery contract with DLA Troop Support Medical valued at up to $999,999,999.00...
This federal contract award, valued at $4,455.68, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp., a major pharmaceutical distributor. The contract is for the delivery of Gadavist, a 10 mmol/10 ml vial medication, with a performance period through May 14, 2024. The contract is a Delivery Order with a Firm Fixed Price pricing type and does not have a set-aside designation, indicating open competition. AmerisourceBergen holds a significant Indefinite Delivery...
  • SPE2DB22D3501
    Indefinite Delivery Contract
  • SPE2DB22D3501-SPE2DB24FWC32
    Delivery Order

This is a delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corporation's Corporate Office division. The $1,747.44 firm-fixed-price contract is for the supply of Gadavist, a medical imaging agent, with a completion date of June 28, 2024. This order is placed under Amerisourcebergen's $999,999,999.00 Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, which serves as the primary vehicle for the company to provide a comprehensive range of pharmaceutical products and medical supplies to DLA facilities supporting the Department of Defense worldwide. The contract does not have a set-aside designation. Amerisourcebergen has also been awarded a smaller IDC with the Department of Justice Federal Bureau of Investigation for similar medical products and prescription drugs, valued up to $750,000 through May 2024.

Generated 9/26/24, 9:38 AM